RIVALEMBIC rivaroxaban 15 mg film-coated tablet blister pack

Ülke: Avustralya

Dil: İngilizce

Kaynak: Department of Health (Therapeutic Goods Administration)

Aktif bileşen:

rivaroxaban, Quantity: 15 mg

Mevcut itibaren:

Alembic Pharmaceuticals Australia Pty Ltd

Farmasötik formu:

Tablet, film coated

Kompozisyon:

Excipient Ingredients: poloxamer; croscarmellose sodium; hypromellose; lactose monohydrate; microcrystalline cellulose; magnesium stearate; titanium dioxide; macrogol 8000; iron oxide red; iron oxide black

Uygulama yolu:

Oral

Paketteki üniteler:

28 tablets, 42 tablets

Reçete türü:

(S4) Prescription Only Medicine

Terapötik endikasyonlar:

Rivaroxaban is indicated for:,? Prevention of venous thromboembolism (VTE) in adult patients who have undergone major orthopaedic surgery of the lower limbs (elective total hip replacement, treatment for up to 5 weeks; elective total knee replacement, treatment for up to 2 weeks),? Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke,? Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and for the prevention of recurrent DVT and PE,Rivaroxaban, in combination with aspirin, is indicated for:,? The prevention of major cardiovascular events (composite of stroke, myocardial infarction and cardiovascular death) in patients with coronary artery disease (CAD) and/or peripheral artery disease (PAD)

Ürün özeti:

Visual Identification: Round shaped, light brown to brown, film-coated biconvex tablets debossed with 15 on one side and I on the other side. Approximately 6 mm in diameter and 3 mm in thickness.; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 6 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Yetkilendirme durumu:

Registered

Yetkilendirme tarihi:

2023-10-03